|
|
||||||||
Ann Thorac Surg 2007;83:1707-1712
© 2007 The Society of Thoracic Surgeons
a Medical City Dallas Hospital, Dallas, Texas
b Cardiopulmonary Research Science and Technology Institute, Dallas, Texas
c Presbyterian Hospital of Dallas, Dallas, Texas
Accepted for publication December 18, 2006.
* Address correspondence to Dr Herbert, Medical City Dallas Hospital, 7777 Forest Lane, Suite C-740, Dallas, TX 75230 (Email: herbert{at}healthcare.com).
Presented at the Fifty-second Annual Meeting of the Southern Thoracic Surgical Association, Orlando FL, Nov 1012, 2005.
| Abstract |
|---|
|
|
|---|
Methods: Data were extracted from our Society of Thoracic Surgeons Database on 19,620 patients undergoing CABG between January 1995 and July 2006. We used perioperative risk factors to develop a logistic regression equation predictive for the development of postoperative atrial fibrillation. A total of 19,083 patients had complete data and were used to construct the final model. The model was used to compare the predicted probability of atrial fibrillation with the known outcome in the patients divided into deciles by probability. Bootstrap procedures were used to determine the confidence limits of the ß coefficients.
Results: A regression model was developed with 14 significant indicators. Those showing the greatest predictive influence included the patient age, the need for prolonged ventilation (24 hours or more), the use of cardiopulmonary bypass, and preoperative arrhythmias. The model showed acceptable concordance between observed and predicted (72.3%), a receiver operating characteristic curve area of 0.72, and Hosmer-Lemeshow probability of 0.19. When applied to the patient population, the calculated risk in those who did not develop AF was 0.179 ± 0.116 and for those with AF, 0.284 ± 0.153 (p < 0.001).
Conclusions: A validated predictive risk algorithm for developing postoperative atrial fibrillation can reliably stratify patients undergoing CABG into high-risk and low-risk groups. This may be used preoperatively to appropriately target high-risk patients for aggressive prophylactic treatment.
| Introduction |
|---|
|
|
|---|
Owing to advances in surgery, anesthesia, and postoperative careand despite a trend for patients undergoing these procedures to be of higher riskoperative mortality and morbidity remain low and, in fact, have declined in recent years [10, 11]. Despite this general decline in complications, the incidence of postoperative atrial fibrillation has not decreased and has actually appeared to be increasing, most likely attributable to the increasing proportions of CABG procedures performed in elderly patients [6, 8].
Although commonly regarded as a benign, self-limiting complication not associated with increased mortality, atrial fibrillation may result in significant morbidity, including hypertension, palpitations, pain, fatigue, dyspnea, or generalized anxiety. Postoperative atrial fibrillation is also associated with congestive heart failure, renal insufficiency, prolonged ventilation, readmission to the intensive care unit, and a threefold to fourfold increased risk of early postoperative stroke [6, 8]. Studies have shown that postoperative atrial fibrillation resulted in longer intensive care unit (ICU) stays, an increased risk of readmission to the ICU, prolonged hospital stay, and increased hospital costs [3, 8, 12]. Atrial fibrillation is also the leading cause of hospital readmission after hospital discharge following cardiac surgery [13].
Because of the enormous clinical and economic impact of this complication, numerous attempts have been made to identify risk factors for postoperative atrial fibrillation in an effort to not only provide insight into pathophysiology but also allow better assessment of prophylactic treatment strategies by directing treatment at those patients most likely to benefit. Identifying a population of patients who are at increased risk for developing postoperative atrial fibrillation would allow for a more targeted preventative or therapeutic intervention strategy that would reduce the potential for antiarrhythmic-related toxicity and decrease the overall cost of prophylactic treatment [14, 15]. Towards this goal, we sought to develop a risk algorithm by using readily available preoperative, intraoperative, and early postoperative indicators for predicting postoperative atrial fibrillation in patients undergoing CABG.
| Patients and Methods |
|---|
|
|
|---|
A retrospective review of data collected by CRSTI on all patients undergoing cardiac operations between January 1, 1995, and July 31, 2006, identified 19,620 patients that underwent isolated CABG surgery; of these, 19,083 had complete data that contributed to the model building. The North Texas Institutional Review Board at Medical City Dallas Hospital approved the study. Patients with postoperative atrial fibrillation were determined from the selected database field (Comps-Other-A-Fib) defined as "patient had a new onset of atrial fibrillation/flutter (AF) requiring treatment. Does not include recurrence of AF which had been present preoperatively."
Patients with a preoperative history of atrial dysrhythmias, defined as atrial fibrillation/flutter requiring treatment within 2 weeks before surgery, were excluded to avoid confusing the incidence of postoperative atrial fibrillation with recurrence of their preexisting condition. Patients with a postoperative length of stay of less than 2 days were also excluded owing to an inability to accurately determine the incidence of postoperative atrial fibrillation in this group. Changes in the STS database definitions during the period studied required that some fields that are now ordinal be redefined as a binary variable so that the data could be appropriately matched.
Statistical Analysis
Patients were grouped by the presence or absence of postoperative atrial fibrillation, and all preoperative as well as selected intraoperative and postoperative variables were compared between groups. Categorical variables were tested using either the
2 or the Fisher exact test, where appropriate, and continuous variables were tested with the two-tailed Student t test using the statistical software SAS 9.1.3 (SAS Institute, Cary, NC). Values of p
0.05 were considered significant. Those variables demonstrating statistical significance between the groups by univariate analysis were used as a starting point in building the predictive model (Table 1), recognizing that some of these variables would ultimately be not significant in the final model when controlling for other variables.
|
The calculated probabilities were then divided into deciles between 0 and 1, and the number of patients predicted to have postoperative atrial fibrillation within each decile was compared with the observed incidence. A bootstrap procedure was run 1000 times, and 95% confidence limits for the coefficients calculated. Finally, probabilities were calculated for all records in the data set, and the predicted was compared with the observed.
| Results |
|---|
|
|
|---|
The final predictive model had 14 variables that provided statistically significant coefficients and odds ratios. Table 2
lists the variables and their ß coefficients, and the odds ratios are given in Table 3. The results of the bootstrap analysis are shown as 95% confidence intervals for the coefficients. For the final model, the receiver operating characteristic curve (ROC), or c statistic, was 0.72, and the Hosmer-Lemeshow test had a
2 value of 11.2 (p = 0.19), showing a good fit for the model.
|
|
Use of the algorithm to decide on initiating treatment before atrial fibrillation starts requires that the patients be divided into high-risk and low-risk groups according to a cutoff value of the calculated probability. High-risk patients could begin prophylactic treatment immediately after surgery. Table 4 presents the effect of varying this breakpoint. Raising the value makes the treatment of the high-risk group more selective, but at the price of placing more atrial fibrillation cases in the low-risk group. Lowering the breakpoint to the median increases the number of patients treated in the high-risk group, but the number of expected cases of atrial fibrillation in the low-risk group drops to 10%.
|
|
| Comment |
|---|
|
|
|---|
It is our intent to clinically validate the algorithm by selecting a threshold probability, above which all patients will be treated prophylactically to prevent atrial fibrillation. Patients admitted for surgery will have their probability calculated, with prolonged ventilation scored as a "No." If the calculated probability is above the threshold, prophylactic treatment is initiated at the end of the operation; otherwise, the patients will not be treated unless the development of prolonged ventilation drives the probability above the threshold value, at which time prophylactic treatment would be initiated.
A major problem in developing the model was that the STS definition of preoperative arrhythmia, which includes atrial fibrillation, was based on short-term observation. In the data definitions used before 2004 (section F, pages 367, version 2.41; http://www.ctsnet.org/file/241DataSpecs.pdf), the field only asked about the 2-week period before the patients cardiac surgery:
ArrhythmiaIs there a preoperative arrhythmia present within two weeks of the procedure, by clinical documentation of any one of the following:
Atrial fibrillation/flutter requiring Rx; etc, with the child field containing the type of arrhythmia.
Arrhythmia TypeWhich arrhythmia is present within two weeks of the procedure; choose one: Atrial fibrillation/flutter requiring Rx. etc.
Since 2004, version 2.52 of the definition (Section F, page 301, http://www.ctsnet.org/file/rptDataSpecifications252_1_ForVendorsPGS.pdf) has been broader, asking about the reported history but still limiting the arrhythmia type data to a 2-week period. Thus, patients with paroxysmal atrial fibrillation could have a "yes" to arrhythmia but "none" to the type if they did not have an occurrence within the 2-week window.
ArrhythmiaIndicate whether there is a history of preoperative arrhythmia (sustained ventricular tachycardia, ventricular fibrillation, atrial fibrillation, atrial flutter, third degree heart block) that has been clinically documented or treated with any of the following treatment modalities:
- 1 ablation therapy
- 2 AICD
- 3 pacemaker
- 4 pharmacological treatment
- 5 electrocardioversion
Arrhythmia TypeIndicate which arrhythmia is present within two weeks of the procedure; choose one:
- Sustained ventricular tachycardia or ventricular fibrillation requiring cardioversion and/or IV amiodarone
- Third degree heart block
- Atrial fibrillation/flutter requiring Rx
- None
We attempted to eliminate patients who had any record of atrial fibrillation preoperatively, but the collected data might not have indicated all the patients. Because the prevalence in the population is estimated at 0.95% [17], the number of patients with preoperative atrial fibrillation who were inadvertently included might not have been large. We were unable to estimate the number accurately, however.
Prospectively identifying patients at increased risk for developing postoperative atrial fibrillation should allow a more accurate assessment of preventive interventions, focus treatment on those most likely to benefit, minimize unnecessary treatment, and maximize treatment value. To that end, a weighted variable algorithm consisting of 14 readily obtainable clinical indicators was created to determine the predicted risk of postoperative atrial fibrillation developing in patients undergoing CABG. The model was derived from a large population and demonstrates acceptable accuracy and concordance, good selectivity (ROC = 0.722), and calibration (Hosmer-Lemeshow
2 = 9.8, p = 0.28). Prospective validation in other populations is warranted and planned. [14, 15]
| Discussion |
|---|
|
|
|---|
DR MAGEE: I have to go back and look at that myself, because that was not a very strong factor. The use of digoxin did correlate with the development of AF. It was the use of digoxin that was associated with the development of AF.
DR GUYTON: And it was twice as strong as preoperative beta-blocker use, and in the case of beta-blocker use, preoperative beta-blocker use was associated with non-development or with development of A-fib?
DR MAGEE: It was associated with the development of AF.
DR TARA KARAMLOU (Toronto, Ontario, Canada): I also thought your statistical analysis was excellent. I just wonder with the trend toward developing minimum data sets with accurate discrimination whether you took into account correlation or redundancy? Many of your variables are probably not in fact independent, and I wonder if a more parsimonious model could be created without loss of predictive ability by removing some of these terms that are highly correlated?
DR MAGEE: I am not sure I can answer that. We did test the model in multiple ways. We used stepwise regression and we did remodel the model multiple times to try to find the best fit, and it was a challenge, because there is a lot of interaction, and you can see that the univariate analysis factors did not necessarily correlate in the end with the multivariate analysis. We did try to include those factors that we thought clinically might have significance even though they didnt necessarily fall out statistically in the univariate analysis.
DR WILLIAM A. BAUMGARTNER (Baltimore, MD): Great presentation. What is your prophylactic regimen, because you said using it you would expect a 60% reduction? Would you mind sharing that with us?
DR MAGEE: That was an assumption basically and we have not validated this prospectively with a treatment regimen. That was based on the literature. We used IV amiodarone or PO amiodarone, and there are a variety of studies that have been done in the literature, and really that is the only one that has been prospectively validated to be beneficial in decreasing length of stay and decreasing the postoperative incidence of atrial fibrillation. The ranges in the literature are anywhere from 7% up to 74% effectiveness in using that regimen, and it is certainly higher if you use postoperative beta-blockers. What we propose and what we intend to do prospectively is to treat all patients with amiodarone. And apparently, again from my reading of the literature, it doesnt matter whether you treat them right after surgery or within the first 24 hours after surgery, because one of our factors is prolonged ventilation, and so that may pull some people in at that 20% level or above by staying on the vent, and we would plan to treat those patients at that point.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Banach, G. Mariscalco, M. Ugurlucan, D. P. Mikhailidis, M. Barylski, and J. Rysz The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation--still underestimated opponent Europace, November 1, 2008; 10(11): 1266 - 1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Banach, A. Goch, M. Misztal, J. Rysz, R. Jaszewski, and J. H. Goch Predictors of paroxysmal atrial fibrillation in patients undergoing aortic valve replacement. J. Thorac. Cardiovasc. Surg., December 1, 2007; 134(6): 1569 - 1576. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |